Close Menu

NEW YORK – Trinity Biotech said today that its second quarter revenues declined 10 percent year over year, driven largely by a drop in point-of-care product sales.

For the three months ended June 30, the Dublin-based firm posted $22.5 million in total revenues, down from $25.0 million in Q2 2018. Point-of-care revenues declined 90 percent to $2.1 million from $4.0 million a year ago, while clinical laboratory revenues dropped to $20.4 million, down 3 percent year over year from $21.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.